Alzinova Phase II ALZ-101 Alzheimer’s vaccine trial accepted for CTAD 2026 poster presentation

PUBT · 1d ago
Alzinova Phase II ALZ-101 Alzheimer’s vaccine trial accepted for CTAD 2026 poster presentation
  • Alzinova secured a poster slot at the CTAD conference in Boston on Nov. 16-19, 2026 for its ALZ-101 Phase II trial.
  • Results have not been presented; the poster will present the ADVANCE Phase 2a study design rather than clinical outcomes.
  • The randomized, double-blind, placebo-controlled trial targets early Alzheimer’s disease, with therapeutic effect as the primary endpoint.
  • Operational start-up has begun, with first patient enrollment targeted around the turn of 2026/2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzinova AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.